UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genome-wide association study and polygenic risk score analysis of esketamine treatment response

Scientific reports, 2020-07, Vol.10 (1), p.12649-12649, Article 12649

2020

Volltextzugriff (PDF)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Psychopharmacology, 2018-04, Vol.235 (4), p.1107-1119

2018

Volltextzugriff (PDF)

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants

Clinical therapeutics, 2014-05, Vol.36 (5), p.698-710

2014

Volltextzugriff (PDF)

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor

Clinical therapeutics, 2015-03, Vol.37 (3), p.610-628.e4

2015

Volltextzugriff (PDF)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine

International journal of methods in psychiatric research, 2022-12, Vol.31 (4), p.e1927-n/a

2022

Volltextzugriff (PDF)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study

Psychopharmacology, 2017-11, Vol.234 (21), p.3175-3183

2017

Volltextzugriff (PDF)

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants

Clinical therapeutics, 2016-01, Vol.38 (1), p.89-98.e1

2016

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

International journal of clinical pharmacology and therapeutics, 2015-06, Vol.53 (6), p.438-446

2015

Volltextzugriff (PDF)

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

The journal of clinical psychiatry, 2020-04, Vol.81 (3)

2020

Volltextzugriff (PDF)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

CNS drugs, 2020-03, Vol.34 (3), p.299-310

2020

Volltextzugriff (PDF)

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study

The international journal of neuropsychopharmacology, 2021-12, Vol.24 (12), p.965-976

2021

Volltextzugriff (PDF)

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

The international journal of neuropsychopharmacology, 2023-03, Vol.26 (3), p.198-206

2023

Volltextzugriff (PDF)

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

The international journal of neuropsychopharmacology, 2020-07, Vol.23 (7), p.426-433

2020

Volltextzugriff (PDF)

Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study

The American journal of geriatric psychiatry, 2022-05, Vol.30 (5), p.541-556

2022

Volltextzugriff (PDF)

Post hoc analyses of an open-label long-term study of esketamine nasal spray plus an oral antidepressant comparing results in older versus younger adults with treatment-resistant depression

The American journal of geriatric psychiatry, 2021-04, Vol.29 (4), p.S127-S128

2021

Volltextzugriff (PDF)

Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

International journal of clinical pharmacology and therapeutics, 2015-02, Vol.53 (2), p.129-138

2015

Volltextzugriff (PDF)

142 Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients with Treatment-resistant Depression

CNS spectrums, 2020-04, Vol.25 (2), p.290-290

2020

Volltextzugriff (PDF)

Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants

International journal of clinical pharmacology and therapeutics, 2015-03, Vol.53 (3), p.256-264

2015

Volltextzugriff (PDF)

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

International journal of clinical pharmacology and therapeutics, 2015-02, Vol.53 (2), p.115-128

2015

Volltextzugriff (PDF)

Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content

Journal of magnetic resonance imaging, 2009-08, Vol.30 (2), p.444-448

2009

Volltextzugriff (PDF)

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

Clinical pharmacology in drug development, 2015-05, Vol.4 (3), p.226-236

2015

Volltextzugriff (PDF)

Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks

Canadian journal of diabetes, 2013-10, Vol.37, p.S27-S27

2013

Volltextzugriff (PDF)

Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus (T2DM) Subjects With Moderate Renal Impairment

Canadian journal of diabetes, 2012-10, Vol.36 (5), p.S40-S41

2012

Volltextzugriff (PDF)

Nested polymerase chain reaction study of 53 cases with Turner's syndrome : is cytogenetically undetected Y mosaicism common ?

The journal of clinical endocrinology and metabolism, 1995-12, Vol.80 (12), p.3532-3536

1995

Volltextzugriff (PDF)

Melatonin affects proopiomelanocortin gene expression in the immune organs of the rat

European journal of endocrinology, 1995-12, Vol.133 (6), p.754-760

1995

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(53)
Buchkapitel
(2)

Sprache

Englisch
(54)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Genome-wide association study and polygenic risk score analysis of esketamine treatment response

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study

Post hoc analyses of an open-label long-term study of esketamine nasal spray plus an oral antidepressant comparing results in older versus younger adults with treatment-resistant depression

Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

142 Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients with Treatment-resistant Depression

Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks

Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus (T2DM) Subjects With Moderate Renal Impairment

Nested polymerase chain reaction study of 53 cases with Turner's syndrome : is cytogenetically undetected Y mosaicism common ?

Melatonin affects proopiomelanocortin gene expression in the immune organs of the rat

Suchergebnisse filtern